Soluble CD163 may be a predictive biomarker of the efficacy of nivolumab plus chemotherapy in patients with HER2-negative metastatic breast cancer (WJOG9917BTR)

被引：1
|
作者：
Mukohara, Toru
Ozaki, Yukinori
Kitano, Shigehisa
Yamashita, Makiko
Ikarashi, Daiki
Tsurutani, Junji
Iwasa, Tsutomu
Takahashi, Masato
Masuda, Norikazu
Futamura, Manabu
Minami, Hironobu
Matsumoto, Koji
Tanabe, Yuko
Kawabata, Hidetaka
Yoshimura, Kenichi
Takano, Toshimi
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-P5-02-42
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P5-02-42
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Biomarker study of patients with HER2-negative metastatic breast cancer receiving combination therapy with nivolumab, bevacizumab and paclitaxel as first-line treatment (WJOG9917BTR)
    Ozaki, Y.
    Kitano, S.
    Matsumoto, K.
    Takahashi, M.
    Mukohara, T.
    Futamura, M.
    Masuda, N.
    Tsurutani, J.
    Yoshimura, K.
    Minami, H.
    Takano, T.
    CANCER RESEARCH, 2019, 79 (04)
  • [2] Safety and efficacy of nivolumab plus bevacizumab, paclitaxel for HER2-negative metastatic breast cancer: Primary results and biomarker data from a phase 2 trial (WJOG9917B)
    Ozaki, Yukinori
    Tsurutani, Junji
    Mukohara, Toru
    Iwasa, Tsutomu
    Takahashi, Masato
    Tanabe, Yuko
    Kawabata, Hidetaka
    Masuda, Norikazu
    Futamura, Manabu
    Minami, Hironobu
    Matsumoto, Koji
    Yoshimura, Kenichi
    Kitano, Shigehisa
    Takano, Toshimi
    EUROPEAN JOURNAL OF CANCER, 2022, 171 : 193 - 202
  • [3] Immunological analysis of the combination therapy of nivolumab, paclitaxel and bevacizumab in patients with HER2negative MBC in NEWBEAT trial (WJOG9917BTR)
    Ozaki, Yukinori
    Kitano, Shigehisa
    Tsurutani, Junji
    Iwasa, Tsutomu
    Takahashi, Masato
    Mukohara, Toru
    Masuda, Norikazu
    Futamura, Manabu
    Minami, Hironobu
    Matsumoto, Koji
    Kawabata, Hidetaka
    Yamashita, Makiko
    Yoshimura, Kenichi
    Takano, Toshimi
    CANCER RESEARCH, 2021, 81 (04)
  • [4] Difference of immunological status and response to immune checkpoint inhibitor between recurrent and de novo stage IV HER2-negative breast cancer in NEWBEAT trial (WJOG9917BTR)
    Ozaki, Y.
    Kitano, S.
    Yamashita, M.
    Ikarashi, D.
    Tsurutani, J.
    Iwasa, T.
    Takahashi, M.
    Mukohara, T.
    Masuda, N.
    Futamura, M.
    Minami, H.
    Matsumoto, K.
    Hashimoto, Y. Tanabe
    Kawabata, H.
    Yoshimura, K.
    Takano, T.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S654 - S654
  • [5] Predictive markers for efficacy of everolimus plus exemestane in patients with luminal HER2-negative metastatic breast cancer
    Okazaki, Misato
    Horimoto, Yoshiya
    Tanabe, Masahiko
    Ichikawa, Yuko
    Tokuda, Emi
    Arakawa, Atsushi
    Kobayashi, Toshiyuki
    Saito, Mitsue
    MEDICAL ONCOLOGY, 2018, 35 (04)
  • [6] Predictive markers for efficacy of everolimus plus exemestane in patients with luminal HER2-negative metastatic breast cancer
    Misato Okazaki
    Yoshiya Horimoto
    Masahiko Tanabe
    Yuko Ichikawa
    Emi Tokuda
    Atsushi Arakawa
    Toshiyuki Kobayashi
    Mitsue Saito
    Medical Oncology, 2018, 35
  • [7] A multicenter phase II study evaluating the efficacy of nivolumab plus paclitaxel plus bevacizumab triple-combination therapy as a first-line treatment in patients with HER2-negative metastatic breast cancer: WJOG9917B NEWBEAT trial
    Ozaki, Yukinori
    Mukohara, Toru
    Tsurutani, Junji
    Takahashi, Masato
    Matsumoto, Koji
    Futamura, Manabu
    Masuda, Norikazu
    Kitano, Shigehisa
    Yoshimura, Kenichi
    Minami, Hironobu
    Takano, Toshimi
    CANCER RESEARCH, 2020, 80 (04)
  • [8] The real-world efficacy and safety of nivolumab plus chemotherapy in patients with HER2-negative advanced gastric cancer
    Yu-Yin Liu
    Ming-Yen Tsai
    Ting-Ting Liu
    Yueh-Wei Liu
    Yu-Hung Lin
    Cheng-Hsi Yeh
    Yu-Cheng Lin
    Yen-Hao Chen
    BMC Cancer, 24 (1)
  • [9] Phase II study of a combination therapy of nivolumab, bevacizumab and paclitaxel in patients with HER2-negative metastatic breast cancer as a first-line treatment (WJOG9917B, NEWBEAT trial).
    Ozaki, Yukinori
    Matsumoto, Koji
    Takahashi, Masato
    Mukohara, Toru
    Futamura, Manabu
    Masuda, Norikazu
    Tsurutani, Junji
    Yoshimura, Kenichi
    Minami, Hironobu
    Takano, Toshimi
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [10] Nimbus: A phase 2 trial of nivolumab plus ipilimumab for patients with hypermutated her2-negative metastatic breast cancer (MBC)
    Barroso-Sousa, Romualdo
    Li, Tianyu
    Reddy, Sangeetha
    Emens, Leisha A.
    Overmoyer, Beth
    Lange, Paulina
    Dilullo, Molly K.
    Attaya, Victoria
    Kimmel, Jeffrey
    Winer, Eric P.
    Mittendorf, Elizabeth A.
    Tayob, Nabihah
    Tolaney, Sara M.
    CANCER RESEARCH, 2022, 82 (04)
12345